Dr. Iman Khalid Almansour Alzamil

Biography

Dr. Iman Almansour Alzamil received Ph.D. degree in Biomedical Engineering & Biotechnology from University of Massachusetts, USA. In addition, she completed the Executive Program for Senior Life Science leaders at Harvard Medical School, Harvard University, USA. 

She has over 15 years of research experience in the development of the next generation vaccine candidates. By integrating interdisciplinary approaches of Genetic engineering, bioinformatics, and immunology, she led the development of several novel nucleic acid vaccines against emerging and re-emerging viruses. She established the Nucleic Acid Vaccine Laboratory (NAVL) at Department of Epidemic Diseases Research at the Department of Epidemic Diseases Research and the Clinical Biomanufacturing Facility (CBMF) at IRMC, IAU.  Her research was published in peer reviewed journals. Furthermore, she boasts patent portfolio that include the next generation of pDNA and mRNA vaccine candidates against SARS-CoV-2, MERS-CoV, and Zika.

 Dr. Almansour Alzamil serves as a member at international organizations including International Society for Vaccines (USA) since 2012, European Virus Bioinformatic Center (Germany) since 2020, and ECA for GMP compliance (Germany) since 2022. 

Research Focus 

• Development of innovative, rationally designed vaccine candidates, such as pDNA and mRNA vaccines against emerging, re-emerging viruses, and cancers. 
• Pre-GMP process development and GMP biomanufacturing to transition the production of novel vaccine candidates from research-grade to phase I/II clinical trials. 
• First-in-human clinical trials for the safety and efficacy evaluation of vaccine candidates.